We have many new drugs to treat metastatic castrate resistant prostate cancer (mCRPC), but not all men have a positive result to each of the drug. Understanding who might obtain a positive result to a specific drug prior giving it will save both the individual man and society time and money.

Understanding this it becomes clear that we neeed to develop ways to identify those men who are more likely to benefit from a particular therapy prior to starting it. In an attempt to move tis goal forward, researchers reviewed the outcome of men treated with abiraterone (Zytiga) at their Institution to describe factors predictive for response.

They identified the men with CRCP who were treated with abiraterone. From electronic records they identified the baseline variables and potential prognostic factors in this group. They evaluated the outcome measures in these men, they included overall survival